For the quarter ending 2025-09-30, PCSA had -$628,200 decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -3,436,573 | -6,768,323 |
| Depreciation | 301 | 602 |
| Non-cash lease expense for right-of-use assets | 24,318 | 46,359 |
| Stock-based compensation | 303,047 | 430,962 |
| Prepaid expenses and other | 55,606 | -745,834 |
| Operating lease liability | -21,832 | -45,073 |
| Accounts payable | -58,582 | -95,126 |
| Due from related parties | - | 0 |
| Accrued expenses | -239,437 | 684,512 |
| Net cash used in operating activities | -3,484,364 | -5,000,253 |
| Net proceeds from the sale of stock and exercise of warrants | 2,859,916 | 10,758,802 |
| Shares withheld to pay taxes on stock-based compensation | 0 | 10,404 |
| Payment of finance lease obligation | 3,752 | 2,850 |
| Settlement of stock award | - | 0 |
| Net cash provided by financing activities | 2,856,164 | 10,745,548 |
| Net increase (decrease) in cash and cash equivalents | -628,200 | 5,745,295 |
| Cash and cash equivalents at beginning of period | 1,191,325 | - |
| Cash and cash equivalents at end of period | 6,308,420 | - |
Processa Pharmaceuticals, Inc. (PCSA)
Processa Pharmaceuticals, Inc. (PCSA)